/
Neurology
Polyneuropathy
17
Pipeline Programs↗
21
Active Trials↗
31
Companies Involved↗
Polyneuropathy is an emerging landscape with 17 programs across 31 companies. The most active players are Qilu Pharmaceutical Co., Ltd., Alnylam Pharmaceuticals. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 12
Phase 38
Approved
No programs
Analysis
Modality Breakdown
62%
Small molecule
8 of 13 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 94% of 17 pipeline programs.
Analysis
Trial Status
81
clinical trials
Completed43 · 53%
Recruiting15 · 19%
Unknown status6 · 7%
Terminated4 · 5%
Withdrawn4 · 5%
Active, not recruiting3 · 4%
Other6 · 7%
Clinical Trials
Trial Activity
81 trials
Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Recruiting·—·Phase 3·NCT06714838·100 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)